Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to IL-4Rα Inhibitors

NCT07550452 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT07550452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07550452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to IL-4Rα Inhibitors
Lead sponsor
Peking University People's Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
March 31, 2026
Completion date
July 31, 2027
Enrollment
300 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis (ad)